Clin Asst Prof Zhang Zewen

About

Dr Zhang Zewen is a Medical Oncologist in NCCS sub-specializing in Breast cancer and Gynecological cancer. He is part of the Cancer Genetics Service team involved in research related to hereditary cancer predisposition syndromes, including Hereditary Breast and Ovarian Cancer and Lynch syndrome. In addition, he also serves as educator in both Duke-NUS Graduate Medical School and Yong Loo Lin School of Medicine, and is active in teaching for medical students, registrars and nurses.

Education and Training

• Member of Royal College of Physicians (Edinburgh); Master of Medicine (Internal Medicine) (Singapore), 2016 
• Duke-NUS Graduate Medical School, Doctor of Medicine (MD), 2013 
• 1st Class Honors, Bachelor’s degree, NUS Chemical Engineering, 2009

Professional Appointments and Committee Memberships

• Institution Committee of Advanced Practice Nurse (APN) Competence (CAC), 2023 to current 
• IBRCA Forum Co-Chair, 2022 to current

Awards

• Academic Clinical Programme (ACP) Programme Grants, Oncology, Education support, 2024 
• Outstanding Resident Award (RISE), Medical Oncology, 2018 
• SingHealth Seah Cheng Siang Gold Medal in Medicine, Duke-NUS Graduate Medical School, 2013 
• Duke-NUS Humanism Award, Duke-NUS Graduate Medical School, 2013 
• Singapore Medical Association-Lee Foundation Teamsmanship Award, Duke-NUS Graduate Medical School, 2013

Publications

• Chan JY, Zhang Z, Chew W, Tan GF, Lim CL, Zhou L, Goh WL, Poon E, Somasundaram N, Selvarajan S, Sittampalam K, Chin F, Teh J, Tan MH, Soo KC, Teo M, Farid M, Quek R. Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma. Sci Rep. 2018 Aug 10;8(1):11959. doi: 10.1038/s41598-018-30442-5. PMID: 30097600; PMCID: PMC6086886. 
• Qi TH, Hian OH, Kumaran AM, Tan TJ, Cong TRY, Su-Xin GL, Lim EH, Ng R, Yeo MCR, Tching FLLW, Zewen Z, Hui CYS, Xin WR, Ooi SKG, Leong LCH, Tan SM, Preetha M, Sim Y, Tan VKM, Yeong J, Yong WF, Cai Y, Nei WL; JBCR; Ai3. Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer. Breast Cancer Res Treat. 2022 May;193(1):121-138. doi: 10.1007/s10549-022-06521-7. Epub 2022 Mar 9. PMID: 35262831. 
• Zhang Z, Ishak NDB, Que FVF, Chua ZY, Chan SH, Chiang J, Yie JNY. COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore. Hered Cancer Clin Pract. 2023 Apr 12;21(1):5. doi: 10.1186/s13053-023-00248-2. PMID: 37046302; PMCID: PMC10091319.
• Liew SZH, Ng KW, Ishak NDB, Lee SY, Zhang Z, Chiang J, Ngeow JYY. Geographical, ethnic, and genetic differences in pancreatic cancer predisposition. Chin Clin Oncol. 2023 Jun;12(3):27. doi: 10.21037/cco-23-8. PMID: 37417291. 
• Ishak ND, Shaw T, Li ST, Yuen J, Goh HX, Chua ZY, Suresh P, Que FVF, Zhang Z, Chiang J, Ngeow J. Cancer patients' experience of receiving variant of uncertain significance results: An Asian perspective. J Genet Couns. 2023 Oct 21. doi: 10.1002/jgc4.1813. Epub ahead of print. PMID: 37864575. 
• Ho WK, Hassan NT, Yoon SY, Yang X, Lim JMC, Binte Ishak ND, Ho PJ, Wijaya EA, Ng PP, Luccarini C, Allen J, Tai MC, Chiang J, Zhang Z, See MH, Thong MK, Woo YL, Dunning AM, Hartman M, Yip CH, Mohd Taib NA, Easton DF, Li J, Ngeow J, Antoniou AC, Teo SH. Age-specific breast and ovarian cancer risks associated with germline BRCA1 or BRCA2 pathogenic variants - an Asian study of 572 families. Lancet Reg Health West Pac. 2024 Feb 5;44:101017. doi: 10.1016/j.lanwpc.2024.101017. PMID: 38333895; PMCID: PMC10851205.